FTD and ALS: Genetic Ties that Bind  by Orr, Harry T.
Neuron
PreviewsFTD and ALS: Genetic Ties that BindHarry T. Orr1,*
1Institute for Translational Neuroscience, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis,
MN 55455, USA
*Correspondence: orrxx002@umn.edu
DOI 10.1016/j.neuron.2011.10.001
Curiously, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), seemingly disparate
neurodegenerative disorders, can be inherited together. Two groups (DeJesus-Hernandez et al. and Renton
et al.) show that the long sought after ALS/FTD mutation on chromosomal region 9p is a hexanucleotide
expansion in C90RF72. These studies, plus a study on X-linked ALS/FTD, provide molecular starting points
for identifying pathways that link ALS and FTD pathogenesis.At first glance, onemight think that a para-
lytic disease caused by degeneration of
upper and lower motor neurons, amyotro-
phic lateral sclerosis (ALS), is unlikely to
be linked mechanistically to a disease
that presents with progressive changes
in personality and language, frontotempo-
ral dementia (FTD). Mutations in super-
oxide dismutase 1 (SOD1), TAR DNA-
binding protein (TARDBP or TDP-43),
fused in sarcoma (FUS), optineurin
(OPTN), and valosin-containing protein
(VCP) cause about 25%–30% of typical
familial ALS, and loss-of-function muta-
tions in the secreted growth factor pro-
granulin cause a fraction of familial FTD.
Yet clinically, ALS and FTD frequently
occur in the same family. Moreover, ab-
normal subcellular localization and aggre-
gation of TDP-43 are found in most
patients with ALS and FTD. Perhaps not
surprisingly, this is a landscape that would
attract teams of gene hunters. In this issue
of Neuron, two groups (DeJesus-Hernan-
dez et al., 2011; Renton et al., 2011) show
that the illusive chromosomal region 9p21
form of ALS/FTD is due to an expansion of
a hexanucleotide repeat in the intron of
C90RF72. Combined with the report last
month in Nature by Deng et al. (2011)
that an X-linked form of ALS and ALS/
FTD is caused by mutations in UBQLN2,
there is now strong evidence that these
two disorders are indeed linked by com-
mon pathogenic pathways.
Genetic studies dating back to 2006
indicated that a major locus for ALS/FTD
is located on chromosomal region 9p21
(Vance et al., 2006). Using two distinctive
next-generation DNA sequencing strate-
gies, groups headed by Rosa Rade-
makers and Bryan Traynor identifieda GGGGCC hexanucleotide repeat in the
intron between noncoding exons 1a and
1 b of the long transcript C90RF72 (De-
Jesus-Hernandez et al., 2011; Renton
et al., 2011). Wild-type alleles contain no
more than 23 repeats, whereas affected
alleles have greater than 30 repeats. Iden-
tification of the 9p21 disease-causing
mutation allowed these groups to deter-
mine the frequency of this mutation in
patient populations. The two studies
each clearly show that the repeat expan-
sion in C90RF72 is a major cause of FTD
and ALS. Using material collected at the
Mayo Clinic, the University of British
Columbia, and the University of Califor-
nia-San Francisco DeJesus-Hernandez
et al. (2011) found that this expansion
was in almost 12% of familial FTD and
22.5% of familial ALS. Likewise, Renton
et al. (2011) found that C90RF72 repeat
expansion is associated with 46% of
familial ALS, 21.1% of sporadic ALS,
and 29.3% of FTD in the Finnish popula-
tion. In an outbred European population
they found that one third of ALS patients
have an expanded GGGGCC repeat.
As of now, little is known about
C90RF72. It is highly conserved across
species yet the C90RF72 protein remains
uncharacterized. This likely will change
very quickly. In any case, location of the
GGGGCC repeat within an intron along
with some evidence for alternative
splicing of C90RF72 transcripts brings
into to play a prominent aspect of non-
coding repeat expansion disorders—the
role of RNA metabolism in pathogenesis.
Specifically, the pathogenic role of the
mutant RNA itself becomes a strong
candidate for having a role in the develop-
ment of ALS/FTD.Neuron 72The myotonic dystrophies DM1 and
DM2 are model RNA-mediated disorders
(Todd and Paulson, 2010). Most notably,
DM1, where an expanded CTG repeat in
the 30 UTR of DMPK causes disease,
was instrumental in defining how amutant
RNA can be pathogenic. In the case of
DM1, the general idea is that mutant
RNA sequesters RNA-binding proteins,
thereby disrupting alternative splicing of
their target RNAs. It is this imbalance in
alternative splicing that underlies the
pathogenic phenotypes associated with
DM1. Key experiments supporting this
paradigm for DM1 are:
d The presence of RNA foci in nuclei
of affected cells that include the
RNA-binding protein MBNL1 (mu-
scleblind), whose binding to the
DM1 CTG repeat is enhanced with
repeat expansion.
d The expression of an expanded
CTG repeat in a noncoding region
of another gene results in animal
models with a degenerative pheno-
type similar to that seen in DM1.
d The deletion of MBML1 causes a
disorder with DM1-associated phe-
notypes. Correspondingly, overex-
pression of MBNL1 rescues some
DM1-like phenotypes in animal
models.
d MBNL1-mediated splicing of RNAs
is altered in DM1 tissue.
These features of DM1 will likely form
the foundation for the next experimental
steps to be pursued with C90RF72 and
its role in ALS/FTD. In fact, the observa-
tion by DeJesus-Hernandez et al. (2011)
that C90RF72 nuclear RNA foci can be
detected in ALS/FTD patient tissue is an, October 20, 2011 ª2011 Elsevier Inc. 189
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rolling. Among the more crucial next
points will be to determine whether the
C90RF72 RNA is pathogenic and, if so,
identify proteins to which it binds.
Given that TDP-43 pathology is a fea-
ture of ALS/FTD and TDP-43 is a RNA-
binding protein, it would be very parsimo-
nious if TDP-43 were to bind theC90RF72
transcript. However, based on what is
known about the binding of TDP-43 to
target RNAs, i.e., TDP-43 prefers long
clusters of uridine, guanine dinucleotide-
rich regions (Tollervey et al., 2011; Poly-
menidou et al., 2011), it seems unlikely
that it binds directly to the C90RF72
GGGGCC repeat. Alternatively, TDP-43
might bind to other regions of the
C90RF72 transcript or be in a complex
with another RNA-binding protein that
does bind to the C90RF72 transcript.
What about UBQLN2 and the X-linked
form of ALS and ALS/FTD reported by
Deng et al. (2011)? Clearly, the presence
of an additional genetic locus where mu-
tations lead to patients with ALS and
FTD together strengthens the concept
that these apparently divergent disorders
are related mechanistically. However, a
pivotal question is whether it provides
any further insight into mechanism(s)
that might link up with C90RF72 and
perhaps a mutant RNA. UBQLN2 en-
codes ubiquilin 2, which is a member of
a family of proteins that have both a ubiq-190 Neuron 72, October 20, 2011 ª2011 Elseuitin-like domain and a ubiquitin-associ-
ated domain. As such, these proteins are
thought to deliver ubiquitinated proteins
to the proteasome for degradation. Two
additional findings by Deng et al. (2011)
are worth noting. First, the ALS/FTD-
associated mutations inUBQLN2, at least
as assessed with transiently transfected
neuro-2a cells, resulted in a decreased
ability to degrade an ubiquitin-protea-
some reporter substrate. In addition,
they also found evidence in transfected
neuro-2A cells that either wild-type or
mutant ubiquilin 2 formed aggregates
with TDP-43. This latter observation
suggests that ubiquilin 2 might in some
way be involved in a TDP-43 pathway. In
this regard, it is worth noting that ubiq-
uitination of TDP-43 is a feature found in
the brains of patients with TDP-43
pathology, e.g., ALS and FTD (Neumann
et al., 2006). Whether ubiquilin 2 functions
in regulating the degradation of TDP-43
would seem to merit exploration.
It is abundantly clear that on many
levels TDP-43 is an important protein
that links ALS with FTD. Thus, under-
standing the function of TDP-43 and
how it is altered in ALS and FTD will be
critical for understanding the pathogen-
esis of these two disorders as well under-
standing why ALS and FTD can present
simultaneously in a patient. The bet is
that elucidation of the pathogenic mecha-
nism stemming from expansion of thevier Inc.hexanucleotide repeat in C90RF72 will
have a pivotal role in putting this puzzle
together. This effort will further under-
score the seminal role RNA processing
plays in neurodegeneration.
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